MEP6408A - Gaba pojačivači u liječenju bolesti i povezanih sa smanjenjem neuresteridnom aktivnošću - Google Patents

Gaba pojačivači u liječenju bolesti i povezanih sa smanjenjem neuresteridnom aktivnošću

Info

Publication number
MEP6408A
MEP6408A MEP-64/08A MEP6408A MEP6408A ME P6408 A MEP6408 A ME P6408A ME P6408 A MEP6408 A ME P6408A ME P6408 A MEP6408 A ME P6408A
Authority
ME
Montenegro
Prior art keywords
treatment
gaba
activity
diseases relating
enhancers
Prior art date
Application number
MEP-64/08A
Other languages
Bosnian (bs)
English (en)
Inventor
Bjarke Ebert
Andersen Peter Hoen-Gaard
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8159857&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MEP6408(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of MEP6408A publication Critical patent/MEP6408A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
MEP-64/08A 2000-11-20 2001-11-20 Gaba pojačivači u liječenju bolesti i povezanih sa smanjenjem neuresteridnom aktivnošću MEP6408A (xx)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200001743 2000-11-20
PCT/DK2001/000773 WO2002040009A1 (en) 2000-11-20 2001-11-20 Gaba enhancers in the treatment of diseases relating to reduced neurosteroid activity

Publications (1)

Publication Number Publication Date
MEP6408A true MEP6408A (xx) 2010-02-10

Family

ID=8159857

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-64/08A MEP6408A (xx) 2000-11-20 2001-11-20 Gaba pojačivači u liječenju bolesti i povezanih sa smanjenjem neuresteridnom aktivnošću

Country Status (34)

Country Link
US (2) US20040024038A1 (de)
EP (1) EP1337247B1 (de)
JP (1) JP4152186B2 (de)
KR (1) KR100865651B1 (de)
CN (1) CN1318027C (de)
AR (1) AR031473A1 (de)
AT (1) ATE336242T1 (de)
AU (2) AU2002223514B2 (de)
BG (1) BG107909A (de)
BR (1) BR0115668A (de)
CA (1) CA2429220C (de)
CY (1) CY1106209T1 (de)
CZ (1) CZ20031383A3 (de)
DE (1) DE60122368T2 (de)
DK (1) DK1337247T3 (de)
EA (1) EA007287B1 (de)
ES (1) ES2266308T3 (de)
HK (1) HK1075010A1 (de)
HR (1) HRP20030404A2 (de)
HU (1) HUP0400505A3 (de)
IL (1) IL155587A0 (de)
IS (1) IS2427B (de)
ME (1) MEP6408A (de)
MX (1) MXPA03004349A (de)
NO (1) NO20032271L (de)
NZ (1) NZ525520A (de)
PL (1) PL361051A1 (de)
PT (1) PT1337247E (de)
SI (1) SI1337247T1 (de)
SK (1) SK7682003A3 (de)
UA (1) UA77403C2 (de)
WO (1) WO2002040009A1 (de)
YU (1) YU39003A (de)
ZA (1) ZA200303289B (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
DE50214447D1 (de) * 2001-11-26 2010-07-01 Finzelberg Gmbh & Co Kg Ingwer-extraktzubereitung
MXPA05013016A (es) * 2003-06-25 2006-03-02 Lundbeck & Co As H Gaboxadol para el tratamiento de la depresion y otros trastornos afectivos.
GB0402118D0 (en) 2004-01-30 2004-03-03 Merck Sharp & Dohme Polymorphic forms of a GABAA agonist
WO2006053556A1 (en) * 2004-06-29 2006-05-26 H. Lundbeck A/S Treatment of neuropathic pain, fibromyalgia or rheumatoid arthritis
WO2006012563A2 (en) * 2004-07-23 2006-02-02 The Regents Of The University Of California Method for the treatment and diagnosis of certain psychiatric disorders related to the menstrual cycle
GB0417558D0 (en) * 2004-08-06 2004-09-08 Merck Sharp & Dohme Novel combination therapy
EP1848420A4 (de) 2005-01-28 2008-01-23 Merck & Co Inc Polymorphe formen eines gabaa-agonisten
US20070122507A1 (en) * 2005-05-26 2007-05-31 Palu Afa K Histone deacetylase and tumor necrosis factor converting enzyme inhibition
US8078688B2 (en) * 2006-12-29 2011-12-13 Prodea Systems, Inc. File sharing through multi-services gateway device at user premises
WO2008141112A1 (en) * 2007-05-09 2008-11-20 Cenerx Biopharma, Inc. Methods of treating rett syndrome
CN101585862B (zh) * 2008-05-20 2014-12-17 梅克芳股份公司 甾族化合物
CN103547240B (zh) * 2011-06-16 2016-03-30 索雷斯生命科学公司 用于人类自主神经系统的平衡和维持健康的系统和方法
RU2496496C1 (ru) * 2012-10-04 2013-10-27 Исаак Григорьевич Гитлин Фармацевтическая композиция, обладающая гамк-ергической активностью
KR20230050474A (ko) * 2016-08-11 2023-04-14 오비드 테라퓨틱스 인크. 간질 장애의 치료를 위한 방법 및 조성물
US20180338959A1 (en) * 2017-05-24 2018-11-29 Ovid Therapeutics Inc. Treatment of depressive disorders
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
KR102049522B1 (ko) * 2018-06-05 2019-11-27 충남대학교산학협력단 Gaba를 유효성분으로 하는 살모넬라 감염질환의 예방 및 치료용 조성물
KR102049526B1 (ko) * 2018-06-05 2019-11-27 충남대학교산학협력단 Gaba를 유효성분으로 하는 항결핵 약학 조성물
EP3833351A4 (de) 2018-09-20 2021-10-13 Ovid Therapeutics Inc. Verwendung von gaboxadol zur behandlung von tourette-syndrom, ticks und stottern
US20220008398A1 (en) 2018-11-21 2022-01-13 Certego Therapeutics Gaboxadol for reducing risk of suicide and rapid relief of depression
CN113423399A (zh) 2018-12-17 2021-09-21 奥维德医疗公司 加波沙朵用于治疗非24小时睡眠-觉醒障碍的用途
AU2020259406A1 (en) 2019-04-17 2021-11-04 Compass Pathfinder Limited Treatment of depression and other various disorders with psilocybin
IL293924A (en) 2019-12-18 2022-08-01 Ovid Therapeutics Inc Goxadol for medical treatment in 1p36 deletion syndrome
KR20230028244A (ko) 2020-05-20 2023-02-28 썰테고 테라퓨틱스 아이엔씨. 고리 중수소화 가복사돌 및 정신 장애의 치료를 위한 이의 용도
CN114404437A (zh) * 2022-03-15 2022-04-29 山东中医药大学 没食子酰芍药苷在制备gabaa受体抑制剂中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4362731A (en) * 1980-09-01 1982-12-07 Sandoz Ltd. Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof
US5120723A (en) * 1987-08-25 1992-06-09 University Of Southern California Method, compositions, and compounds for modulating brain excitability
AU2657292A (en) * 1991-09-13 1993-04-27 Cocensys, Inc. Novel gabaa receptor with steroid binding sites
US5206415A (en) * 1991-12-20 1993-04-27 Washington University Tricyclic steroid analogs
CZ300694A3 (en) * 1993-12-02 1996-05-15 Akzo Nobel Nv Substituted 2beta-morpholinandrostane derivatives, process of their preparation, their use for preparing pharmaceutical preparations and pharmaceutical compositions containing thereof
CZ292881B6 (cs) * 1994-11-23 2003-12-17 Euro-Celtique S.A. Androstanová a pregnanová řada pro allosterickou modulaci GABA receptoru
US5776959A (en) * 1995-06-05 1998-07-07 Washington University Anticonvulsant and anxiolytic lactam and thiolactam derivatives
DE69634039T2 (de) * 1995-06-06 2005-12-08 Euro-Celtique S.A. Steroidderivate der Androstan- und der Pregnanreihe
IT1290003B1 (it) * 1997-03-03 1998-10-19 Angelini Ricerche Spa Uso di pivagabina per preparare composizioni farmaceutiche
GB9801208D0 (en) * 1998-01-21 1998-03-18 Merck Sharp & Dohme Therapeutic agents
AU758808B2 (en) * 1998-07-22 2003-03-27 N.V. Organon Alpha-amino acid phenyl ester derivatives
WO2001042190A1 (en) * 1999-12-08 2001-06-14 Warner-Lambert Company Method for the stereoselective synthesis of cyclic amino acids

Also Published As

Publication number Publication date
EP1337247A1 (de) 2003-08-27
SI1337247T1 (sl) 2006-12-31
UA77403C2 (en) 2006-12-15
HUP0400505A3 (en) 2008-08-28
HRP20030404A2 (en) 2005-04-30
CA2429220C (en) 2009-09-15
AU2002223514B2 (en) 2006-11-30
IS2427B (is) 2008-10-15
PL361051A1 (en) 2004-09-20
HK1075010A1 (en) 2005-12-02
ES2266308T3 (es) 2007-03-01
BG107909A (bg) 2004-08-31
PT1337247E (pt) 2006-11-30
HUP0400505A2 (hu) 2004-07-28
DE60122368T2 (de) 2007-08-09
AU2351402A (en) 2002-05-27
CZ20031383A3 (cs) 2003-08-13
EP1337247B1 (de) 2006-08-16
DK1337247T3 (da) 2006-12-04
AR031473A1 (es) 2003-09-24
SK7682003A3 (en) 2003-10-07
KR20030065517A (ko) 2003-08-06
EA007287B1 (ru) 2006-08-25
ZA200303289B (en) 2005-07-27
KR100865651B1 (ko) 2008-10-29
JP2004513921A (ja) 2004-05-13
CA2429220A1 (en) 2002-05-23
CY1106209T1 (el) 2011-06-08
CN1318027C (zh) 2007-05-30
IL155587A0 (en) 2003-11-23
EA200300594A1 (ru) 2003-10-30
US20090143435A1 (en) 2009-06-04
YU39003A (sh) 2006-05-25
ATE336242T1 (de) 2006-09-15
MXPA03004349A (es) 2003-08-19
BR0115668A (pt) 2003-09-02
US20040024038A1 (en) 2004-02-05
NO20032271D0 (no) 2003-05-20
JP4152186B2 (ja) 2008-09-17
DE60122368D1 (de) 2006-09-28
NZ525520A (en) 2005-04-29
IS6803A (is) 2003-04-30
WO2002040009A1 (en) 2002-05-23
NO20032271L (no) 2003-05-20
CN1592616A (zh) 2005-03-09

Similar Documents

Publication Publication Date Title
MEP6408A (xx) Gaba pojačivači u liječenju bolesti i povezanih sa smanjenjem neuresteridnom aktivnošću
MXPA04004370A (es) Derivados policiclicos de guanina inhibidores de fosfodiesterasa v.
WO2001062234A8 (en) Dosing regimen
AU5584901A (en) Use of cyclic gmp-specific phosphodiesterase inhibitors for treatment of parkinson's disease
HK1094421A1 (en) (S)-2-n-propylamino-5-hydroxytetralin as a d3-agonist
SG166820A1 (en) Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
IN2006KO01346A (de)
TW200630086A (en) Gaba analog prodrug sustained release oral dosage forms
WO2004010987A3 (en) Use of s1p receptor agonists in heart diseases
WO2004006859A3 (en) Platinum compound
MXPA04006031A (es) Compuestos para el tratamiento de trastornos inflamatorios.
AU2002360436A1 (en) 2-aryl pyrrologpyrimidines for a1 and a3 receptors
NO20043013L (no) Tetrahydrokinolin analoger som muskarine agonister
MXPA05000765A (es) Compuestos de 5-ariltetrazola, composiciones de los mismos y usos para los mismos.
DE60332663D1 (de) CCR1-Rezeptor-Antagonisten zur Behandlung u.a. Demyelinisierender entzündlicher Erkrankungen
DE60018186D1 (de) Arzneimittel zur vorbeugung / behandlung / inhibierung des fortschritts für einfache oder preproliferative retinopathie
IL164528A (en) Method for inhibition of atrophy or for treatment or prevention of atrophy related symptoms in women
IL181713A0 (en) Use of il-17f for the treatment and/or prevention of neurological diseases
CY1107697T1 (el) Χρηση της θυλακιοτροπου ορμονης στην μειωση των χρωμοσωμικων ανωμαλιων των σπερματοζωαριων στα αρσενικα
GB0027020D0 (en) Treatment of movement disorders
MXPA04011019A (es) Combinacion de un inhibidor de la bomba de protones y un agente respiratorio, para el tratamiento de trastornos de las vias respiratorias.
PL1828197T3 (pl) Nowe podstawione pochodne tiofenopirymidynonu jako inhibitory dehydrogenazy 17ß-hydroksysteroidowej
DK1536777T3 (da) Anvendelse af NF-KB-inhibitorer til behandling af mastitis
DK1421086T3 (da) 2-(Aminomethyl)-tetrahydro-9-oxa-1,3-diaza-cyclopenta[a]-naphthalenyl-derivater med antipsykotisk aktivitet
BR0211340A (pt) Derivados de 2-(aminometil)-tetraidro-9-oxa-1,3-diaza-ciclopenta[a ]naftalenila com atividade antipsicótica